TRIM4 Expression Related to Malignant Progression and Cisplatin Resistance in Osteosarcoma
Osteosarcoma (OS) is a high-grade intraosseous malignancy. Twenty to thirty percent of OS patients react poorly to standard therapy with a combination of surgical resection and chemotherapy. It is necessary to find molecules that play an important role in this. This study explored the role of TRIM4...
Gespeichert in:
| Veröffentlicht in: | Applied biochemistry and biotechnology 2024, Vol.196 (1), p.233-244 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 244 |
|---|---|
| container_issue | 1 |
| container_start_page | 233 |
| container_title | Applied biochemistry and biotechnology |
| container_volume | 196 |
| creator | Li, Yan Gao, Jie Wang, Dong Liu, Zijin Zhang, Huawu |
| description | Osteosarcoma (OS) is a high-grade intraosseous malignancy. Twenty to thirty percent of OS patients react poorly to standard therapy with a combination of surgical resection and chemotherapy. It is necessary to find molecules that play an important role in this. This study explored the role of TRIM4 in OS chemotherapy sensitivity and malignant progression. The expression of TRIM4 in OS tissues and cells was examined by RT-qPCR, immunohistochemical staining, and western blot. Specific siRNA was transfected into U2-OS and SAOS2 cells to target TRIM4. Cell biological behavior was examined by CCK-8, Transwell, and flow cytometry experiments. Cisplatin-resistant SAOS2 (SAOS2-Cis-R) cells were established, and the effect of TRIM4 expression on the cisplatin response of SAOS2 cells was tested. Knockdown of TRIM4 significantly inhibited the proliferation, migration, and invasion of U2-OS and SAOS2 cells and induced apoptosis. TRIM4 expression was significantly higher in chemotherapy-resistant OS tissues compared to chemotherapy-sensitive OS tissues. Furthermore, the expression of TRIM4 in SAOS2-Cis-R cells was significantly increased compared to parental SAOS2 cells. Moreover, overexpression of TRIM4 enhanced cisplatin resistance in parental SAOS2 cells, while the downregulation of TRIM4 expression enhanced cisplatin sensitivity of SAOS2-Cis-R cells. High TRIM4 expression might be associated with malignant progression and poor response to chemotherapy response of OS. Targeting TRIM4 may be beneficial for OS treatment or combination therapy. |
| doi_str_mv | 10.1007/s12010-023-04551-5 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2807922414</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2915813568</sourcerecordid><originalsourceid>FETCH-LOGICAL-c359t-14b6bedef08530f0052a4333b4e1c230253e99767587a75247d5d26f2d60ec3</originalsourceid><addsrcrecordid>eNqFkU1P3DAQhq0KVLbQP9BDFYkLl5SxJxMnx2rFlwQCAadeLG8yWQVl460nK8G_x7DQSj2UkzX2M6818yj1TcMPDWCPRRvQkIPBHAoindMnNdNEdbqq9Y6agbGYG1PVe-qLyAOANhXZz2oPrdaElZ2pX_e3F1dFdvK4jizShzG75cFP3GZTyK780C9HP07ZTQzLd8CPbTbvZZ2w_gWXXiY_Npyl6lomDuJjE1b-QO12fhD--nbuq7vTk_v5eX55fXYx_3mZN0j1lOtiUS645Q4qQugAyPgCERcF68YgGEKua1taqqy3ZArbUmvKzrQlcIP76mibuo7h94ZlcqteGh4GP3LYiMM0KNVYavwQNRXY2phCFwk9_Ad9CJs4pjFcWi1VGqmsEmW2VBODSOTOrWO_8vHJaXAvitxWkUuK3KsiR6np-1v0ZrHi9k_Lu5ME4BaQ9DQuOf79-z-xz4Q8mds</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2915813568</pqid></control><display><type>article</type><title>TRIM4 Expression Related to Malignant Progression and Cisplatin Resistance in Osteosarcoma</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Li, Yan ; Gao, Jie ; Wang, Dong ; Liu, Zijin ; Zhang, Huawu</creator><creatorcontrib>Li, Yan ; Gao, Jie ; Wang, Dong ; Liu, Zijin ; Zhang, Huawu</creatorcontrib><description>Osteosarcoma (OS) is a high-grade intraosseous malignancy. Twenty to thirty percent of OS patients react poorly to standard therapy with a combination of surgical resection and chemotherapy. It is necessary to find molecules that play an important role in this. This study explored the role of TRIM4 in OS chemotherapy sensitivity and malignant progression. The expression of TRIM4 in OS tissues and cells was examined by RT-qPCR, immunohistochemical staining, and western blot. Specific siRNA was transfected into U2-OS and SAOS2 cells to target TRIM4. Cell biological behavior was examined by CCK-8, Transwell, and flow cytometry experiments. Cisplatin-resistant SAOS2 (SAOS2-Cis-R) cells were established, and the effect of TRIM4 expression on the cisplatin response of SAOS2 cells was tested. Knockdown of TRIM4 significantly inhibited the proliferation, migration, and invasion of U2-OS and SAOS2 cells and induced apoptosis. TRIM4 expression was significantly higher in chemotherapy-resistant OS tissues compared to chemotherapy-sensitive OS tissues. Furthermore, the expression of TRIM4 in SAOS2-Cis-R cells was significantly increased compared to parental SAOS2 cells. Moreover, overexpression of TRIM4 enhanced cisplatin resistance in parental SAOS2 cells, while the downregulation of TRIM4 expression enhanced cisplatin sensitivity of SAOS2-Cis-R cells. High TRIM4 expression might be associated with malignant progression and poor response to chemotherapy response of OS. Targeting TRIM4 may be beneficial for OS treatment or combination therapy.</description><identifier>ISSN: 0273-2289</identifier><identifier>EISSN: 1559-0291</identifier><identifier>DOI: 10.1007/s12010-023-04551-5</identifier><identifier>PMID: 37115387</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Apoptosis ; Biochemistry ; Biotechnology ; Bone cancer ; Bone Neoplasms - drug therapy ; Bone Neoplasms - genetics ; Cell Line, Tumor ; Cell Proliferation ; Chemistry ; Chemistry and Materials Science ; Chemotherapy ; Cholecystokinin ; Cisplatin ; Cisplatin - pharmacology ; Cisplatin - therapeutic use ; drug therapy ; Flow cytometry ; Flow resistance ; Humans ; immunohistochemistry ; Malignancy ; Original Article ; Osteosarcoma ; Osteosarcoma - drug therapy ; Osteosarcoma - genetics ; resection ; Sarcoma ; Sensitivity enhancement ; siRNA ; Western blotting</subject><ispartof>Applied biochemistry and biotechnology, 2024, Vol.196 (1), p.233-244</ispartof><rights>The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><rights>2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c359t-14b6bedef08530f0052a4333b4e1c230253e99767587a75247d5d26f2d60ec3</cites><orcidid>0000-0003-4913-9233</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12010-023-04551-5$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12010-023-04551-5$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27903,27904,41467,42536,51297</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37115387$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Li, Yan</creatorcontrib><creatorcontrib>Gao, Jie</creatorcontrib><creatorcontrib>Wang, Dong</creatorcontrib><creatorcontrib>Liu, Zijin</creatorcontrib><creatorcontrib>Zhang, Huawu</creatorcontrib><title>TRIM4 Expression Related to Malignant Progression and Cisplatin Resistance in Osteosarcoma</title><title>Applied biochemistry and biotechnology</title><addtitle>Appl Biochem Biotechnol</addtitle><addtitle>Appl Biochem Biotechnol</addtitle><description>Osteosarcoma (OS) is a high-grade intraosseous malignancy. Twenty to thirty percent of OS patients react poorly to standard therapy with a combination of surgical resection and chemotherapy. It is necessary to find molecules that play an important role in this. This study explored the role of TRIM4 in OS chemotherapy sensitivity and malignant progression. The expression of TRIM4 in OS tissues and cells was examined by RT-qPCR, immunohistochemical staining, and western blot. Specific siRNA was transfected into U2-OS and SAOS2 cells to target TRIM4. Cell biological behavior was examined by CCK-8, Transwell, and flow cytometry experiments. Cisplatin-resistant SAOS2 (SAOS2-Cis-R) cells were established, and the effect of TRIM4 expression on the cisplatin response of SAOS2 cells was tested. Knockdown of TRIM4 significantly inhibited the proliferation, migration, and invasion of U2-OS and SAOS2 cells and induced apoptosis. TRIM4 expression was significantly higher in chemotherapy-resistant OS tissues compared to chemotherapy-sensitive OS tissues. Furthermore, the expression of TRIM4 in SAOS2-Cis-R cells was significantly increased compared to parental SAOS2 cells. Moreover, overexpression of TRIM4 enhanced cisplatin resistance in parental SAOS2 cells, while the downregulation of TRIM4 expression enhanced cisplatin sensitivity of SAOS2-Cis-R cells. High TRIM4 expression might be associated with malignant progression and poor response to chemotherapy response of OS. Targeting TRIM4 may be beneficial for OS treatment or combination therapy.</description><subject>Apoptosis</subject><subject>Biochemistry</subject><subject>Biotechnology</subject><subject>Bone cancer</subject><subject>Bone Neoplasms - drug therapy</subject><subject>Bone Neoplasms - genetics</subject><subject>Cell Line, Tumor</subject><subject>Cell Proliferation</subject><subject>Chemistry</subject><subject>Chemistry and Materials Science</subject><subject>Chemotherapy</subject><subject>Cholecystokinin</subject><subject>Cisplatin</subject><subject>Cisplatin - pharmacology</subject><subject>Cisplatin - therapeutic use</subject><subject>drug therapy</subject><subject>Flow cytometry</subject><subject>Flow resistance</subject><subject>Humans</subject><subject>immunohistochemistry</subject><subject>Malignancy</subject><subject>Original Article</subject><subject>Osteosarcoma</subject><subject>Osteosarcoma - drug therapy</subject><subject>Osteosarcoma - genetics</subject><subject>resection</subject><subject>Sarcoma</subject><subject>Sensitivity enhancement</subject><subject>siRNA</subject><subject>Western blotting</subject><issn>0273-2289</issn><issn>1559-0291</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNqFkU1P3DAQhq0KVLbQP9BDFYkLl5SxJxMnx2rFlwQCAadeLG8yWQVl460nK8G_x7DQSj2UkzX2M6818yj1TcMPDWCPRRvQkIPBHAoindMnNdNEdbqq9Y6agbGYG1PVe-qLyAOANhXZz2oPrdaElZ2pX_e3F1dFdvK4jizShzG75cFP3GZTyK780C9HP07ZTQzLd8CPbTbvZZ2w_gWXXiY_Npyl6lomDuJjE1b-QO12fhD--nbuq7vTk_v5eX55fXYx_3mZN0j1lOtiUS645Q4qQugAyPgCERcF68YgGEKua1taqqy3ZArbUmvKzrQlcIP76mibuo7h94ZlcqteGh4GP3LYiMM0KNVYavwQNRXY2phCFwk9_Ad9CJs4pjFcWi1VGqmsEmW2VBODSOTOrWO_8vHJaXAvitxWkUuK3KsiR6np-1v0ZrHi9k_Lu5ME4BaQ9DQuOf79-z-xz4Q8mds</recordid><startdate>2024</startdate><enddate>2024</enddate><creator>Li, Yan</creator><creator>Gao, Jie</creator><creator>Wang, Dong</creator><creator>Liu, Zijin</creator><creator>Zhang, Huawu</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7ST</scope><scope>7T7</scope><scope>7TM</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>88I</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>RC3</scope><scope>SOI</scope><scope>7X8</scope><scope>7S9</scope><scope>L.6</scope><orcidid>https://orcid.org/0000-0003-4913-9233</orcidid></search><sort><creationdate>2024</creationdate><title>TRIM4 Expression Related to Malignant Progression and Cisplatin Resistance in Osteosarcoma</title><author>Li, Yan ; Gao, Jie ; Wang, Dong ; Liu, Zijin ; Zhang, Huawu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c359t-14b6bedef08530f0052a4333b4e1c230253e99767587a75247d5d26f2d60ec3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Apoptosis</topic><topic>Biochemistry</topic><topic>Biotechnology</topic><topic>Bone cancer</topic><topic>Bone Neoplasms - drug therapy</topic><topic>Bone Neoplasms - genetics</topic><topic>Cell Line, Tumor</topic><topic>Cell Proliferation</topic><topic>Chemistry</topic><topic>Chemistry and Materials Science</topic><topic>Chemotherapy</topic><topic>Cholecystokinin</topic><topic>Cisplatin</topic><topic>Cisplatin - pharmacology</topic><topic>Cisplatin - therapeutic use</topic><topic>drug therapy</topic><topic>Flow cytometry</topic><topic>Flow resistance</topic><topic>Humans</topic><topic>immunohistochemistry</topic><topic>Malignancy</topic><topic>Original Article</topic><topic>Osteosarcoma</topic><topic>Osteosarcoma - drug therapy</topic><topic>Osteosarcoma - genetics</topic><topic>resection</topic><topic>Sarcoma</topic><topic>Sensitivity enhancement</topic><topic>siRNA</topic><topic>Western blotting</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Li, Yan</creatorcontrib><creatorcontrib>Gao, Jie</creatorcontrib><creatorcontrib>Wang, Dong</creatorcontrib><creatorcontrib>Liu, Zijin</creatorcontrib><creatorcontrib>Zhang, Huawu</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Environment Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Nucleic Acids Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>Genetics Abstracts</collection><collection>Environment Abstracts</collection><collection>MEDLINE - Academic</collection><collection>AGRICOLA</collection><collection>AGRICOLA - Academic</collection><jtitle>Applied biochemistry and biotechnology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Li, Yan</au><au>Gao, Jie</au><au>Wang, Dong</au><au>Liu, Zijin</au><au>Zhang, Huawu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>TRIM4 Expression Related to Malignant Progression and Cisplatin Resistance in Osteosarcoma</atitle><jtitle>Applied biochemistry and biotechnology</jtitle><stitle>Appl Biochem Biotechnol</stitle><addtitle>Appl Biochem Biotechnol</addtitle><date>2024</date><risdate>2024</risdate><volume>196</volume><issue>1</issue><spage>233</spage><epage>244</epage><pages>233-244</pages><issn>0273-2289</issn><eissn>1559-0291</eissn><abstract>Osteosarcoma (OS) is a high-grade intraosseous malignancy. Twenty to thirty percent of OS patients react poorly to standard therapy with a combination of surgical resection and chemotherapy. It is necessary to find molecules that play an important role in this. This study explored the role of TRIM4 in OS chemotherapy sensitivity and malignant progression. The expression of TRIM4 in OS tissues and cells was examined by RT-qPCR, immunohistochemical staining, and western blot. Specific siRNA was transfected into U2-OS and SAOS2 cells to target TRIM4. Cell biological behavior was examined by CCK-8, Transwell, and flow cytometry experiments. Cisplatin-resistant SAOS2 (SAOS2-Cis-R) cells were established, and the effect of TRIM4 expression on the cisplatin response of SAOS2 cells was tested. Knockdown of TRIM4 significantly inhibited the proliferation, migration, and invasion of U2-OS and SAOS2 cells and induced apoptosis. TRIM4 expression was significantly higher in chemotherapy-resistant OS tissues compared to chemotherapy-sensitive OS tissues. Furthermore, the expression of TRIM4 in SAOS2-Cis-R cells was significantly increased compared to parental SAOS2 cells. Moreover, overexpression of TRIM4 enhanced cisplatin resistance in parental SAOS2 cells, while the downregulation of TRIM4 expression enhanced cisplatin sensitivity of SAOS2-Cis-R cells. High TRIM4 expression might be associated with malignant progression and poor response to chemotherapy response of OS. Targeting TRIM4 may be beneficial for OS treatment or combination therapy.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>37115387</pmid><doi>10.1007/s12010-023-04551-5</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0003-4913-9233</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0273-2289 |
| ispartof | Applied biochemistry and biotechnology, 2024, Vol.196 (1), p.233-244 |
| issn | 0273-2289 1559-0291 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2807922414 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Apoptosis Biochemistry Biotechnology Bone cancer Bone Neoplasms - drug therapy Bone Neoplasms - genetics Cell Line, Tumor Cell Proliferation Chemistry Chemistry and Materials Science Chemotherapy Cholecystokinin Cisplatin Cisplatin - pharmacology Cisplatin - therapeutic use drug therapy Flow cytometry Flow resistance Humans immunohistochemistry Malignancy Original Article Osteosarcoma Osteosarcoma - drug therapy Osteosarcoma - genetics resection Sarcoma Sensitivity enhancement siRNA Western blotting |
| title | TRIM4 Expression Related to Malignant Progression and Cisplatin Resistance in Osteosarcoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T07%3A51%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=TRIM4%20Expression%20Related%20to%20Malignant%20Progression%20and%20Cisplatin%20Resistance%20in%20Osteosarcoma&rft.jtitle=Applied%20biochemistry%20and%20biotechnology&rft.au=Li,%20Yan&rft.date=2024&rft.volume=196&rft.issue=1&rft.spage=233&rft.epage=244&rft.pages=233-244&rft.issn=0273-2289&rft.eissn=1559-0291&rft_id=info:doi/10.1007/s12010-023-04551-5&rft_dat=%3Cproquest_cross%3E2915813568%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2915813568&rft_id=info:pmid/37115387&rfr_iscdi=true |